close
MENU
Hot Topic Scrutiny Week
Hot Topic Scrutiny Week
3 mins to read

Biomatters takes advantage of biological drug market

Local software developer says it can help pharmaceutical companies make drugs to target cancer.

Calida Smylie
Mon, 30 Jan 2017

Auckland-based software developer Biomatters has designed an antibody analysis platform, which it says could help pharmaceutical companies make drugs to target diseases such as cancer.

The 13-year-old company, which already has a genetic code data analysis tool called Geneious used by about 3000

Want to read more? It's easy.

Choose your best value subscription option

Student

Exclusive offer for uni students studying at a New Zealand university (valued at $499).
Individual
Group membership
NBR Marketplace

Yearly Premium Online Subscription

NZ$499.00 / yearly

Monthly Premium Online Subscription

NZ$44.95 / monthly

Smartphone Only Subscription

NZ$24.95 / monthly

Premium Group Membership 10 Users

NZ$350+GST / monthly

$35 per user - Pay by monthly credit card debit

Premium Group Membership 20 Users

NZ$600+GST / monthly

$30 per user - Pay by monthly credit card debit

Premium Group Membership 50 Users

NZ$1250+GST / monthly

$25 per user - Pay by monthly credit card debit

Premium Group Membership 100 Users

NZ$1875+GST / monthly

$18.75 per user - Pay by monthly credit card debit

Yearly Premium Online Subscription + NBR Marketplace

NZ$499.00 / yearly

Already have an account? Login
Calida Smylie
Mon, 30 Jan 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Biomatters takes advantage of biological drug market
64461
true